A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new multiple sclerosis drug Mayzent, calling its $88,561 list price “far out of line” compared with its benefits for patients.
U.S. group says Novartis MS drug price out of line with benefit
Website developed in accordance with Web Content Accessibility Guidelines 2.1.
If you encounter any issues while using this site, please contact us: 516.579.6500
If you encounter any issues while using this site, please contact us: 516.579.6500
